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Abstract
Background: The yield of mycobacterial blood cultures for multidrug-resistant (MDR) and extensively drug-resistant
tuberculosis (XDR-TB) among drug-resistant TB suspects has not been described.
Methods: We performed a retrospective, cross-sectional analysis to determine the yield of mycobacterial blood
cultures for MDR-TB and XDR-TB among patients suspected of drug-resistant TB from rural South Africa. Secondary
outcomes included risk factors of Mycobacterium tuberculosis bacteremia and the additive yield of mycobacterial
blood cultures compared to sputum culture.
Results: From 9/1/2006 to 12/31/2008, 130 patients suspected of drug-resistant TB were evaluated with
mycobacterial blood culture. Each patient had a single mycobacterial blood culture with 41 (32%) positive for M.
tuberculosis, of which 20 (49%) were XDR-TB and 8 (20%) were MDR-TB. One hundred fourteen (88%) patients were
known to be HIV-infected. Patients on antiretroviral therapy were significantly less likely to have a positive blood
culture for M. tuberculosis (p = 0.002). The diagnosis of MDR or XDR-TB was made by blood culture alone in 12
patients.
Conclusions: Mycobacterial blood cultures provided an additive yield for diagnosis of drug-resistant TB in patients
with HIV from rural South Africa. The use of mycobacterial blood cultures should be considered in all patients
suspected of drug-resistant TB in similar settings.
Background
Tuberculosis (TB) is the leading cause of mortality
among people living with HIV worldwide [1,2]. Drug-
resistant TB has emerged as an important global threat
to public health. Although previously considered
uncommon in high HIV prevalence settings, there has
been a 3-4 fold increase in multidrug-resistant (MDR)-
TB prevalence in southern Africa over the past decade
[3,4]. In addition, extensively drug-resistant (XDR)-TB
has been reported from all countries in southern Africa.
MDR and XDR-TB are associated with a much higher
mortality than drug-susceptible TB [5], especially among
HIV co-infected persons [6].
Prompt diagnosis and treatment are essential to
improve drug-resistant TB outcomes, but TB diagnosis
in patients with HIV co-infection is challenging, particu-
larly in resource-limited settings [6]. HIV-infected TB
patients have higher rates of extrapulmonary disease,
atypical clinical presentations, and normal chest radio-
graphs [7-10]. With the emergence of MDR and XDR-
TB in HIV-infected populations worldwide [3], it is
therefore likely that there will be a consequent rise in
extrapulmonary MDR and XDR-TB disease [11]. The
diagnosis of drug-resistant TB requires isolation of an
organism, or DNA in the case of molecular tests, thus
vigorous efforts to obtain a specimen that may yield
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Mycobacteremia with drug-susceptible TB was
described in reports from HIV-infected patients early in
the epidemic of HIV from the United States [12,13]. Yet
the yield of blood cultures in detecting M. tuberculosis can
vary between 2%-64% depending on the population of
study and suspicion for extrapulmonary TB [14-19]. In
addition, HIV-infected patients may be predisposed to
other bacterial and fungal bloodstream infections that
clinically mimic TB, leading to delays in diagnosis or over-
treatment of TB. In sub-Saharan Africa, M. tuberculosis
bacteremia has been documented in patients with blood
stream infections from a referral hospital in Tanzania, in
patients with cough from Botswana, and as a critical etiol-
ogy of sepsis among HIV-infected patients from Uganda,
but drug-susceptibility testing (DST) was not performed
[20-22]. To date, no study has reported the yield of blood
cultures for the detection of MDR and XDR-TB.
Over 650 patients with MDR and XDR-TB have been
identified from the rural Tugela Ferry area of KwaZulu-
Natal, South Africa, where HIV co-infection rates
exceed 90% [5,23]. Mycobacterial blood cultures have
been used routinely in Tugela Ferry since 2006 in an
attempt to improve case detection of drug-resistant TB.
We sought to quantify the yield of blood cultures for
MDR and XDR-TB, compare the yield to that of sputum
culture, and identify risk factors for M. tuberculosis bac-
t e r e m i ai nt h i sp o p u l a t i o ni no r d e rt og u i d ec l i n i c a l
practice and public health policy.
Methods
Setting
The Church of Scotland Hospital (COSH) in Tugela
Ferry is a 355-bed facility serving a population of
200,000 Zulu people. The local incidence of TB is esti-
mated at 1,100 per 100,000 population, with approxi-
mately 80% of TB cases being HIV coinfected[24].
Onsite diagnostics include smear microscopy for acid-
fact bacilli of sputum and cerebrospinal fluid specimens.
Sputum and other non-sputum fluid specimens requir-
ing culture and DST are sent to the provincial TB refer-
ral laboratory in Durban (approximately 180 kilometers
away) on a daily basis. Since June 2005, all TB suspects
presenting to COSH are requested to give two ‘spot’
sputum specimens, one for onsite smear microscopy,
and one for mycobacterial culture and DST.
Study design
We performed a retrospective, cross-sectional study of
all drug-resistant TB suspects in whom at least one
mycobacterial blood culture was sent from September
1
st, 2006 to December 31
st, 2008. Clinicians defined a
drug-resistant TB suspect based on the presence of TB
symptoms (e.g., cough, nightsweats, weight loss) with
one or more of the following additional criteria:
advanced HIV/AIDS, a prior history of TB treatment, or
persistent symptoms despite one month or more of
drug-susceptible TB treatment. If a sputum culture was
available it was included for analysis if collected within
two weeks before or after the date of collection of the
blood culture.
Medical chart review was performed to obtain demo-
graphic, clinical and microbiological information. Speci-
fic data extracted included age, gender, HIV status,
receipt and duration of antiretroviral treatment, CD4
cell count (cells/mm
3) prior to blood culture collection,
history of TB treatment, TB treatment status at time of
blood culture collection, and physician’sc o m m e n t so f
signs of extrapulmonary TB.
Definitions and outcome measures
Patients were categorized as being extrapulmonary TB
suspects if a physician had documented specific extra-
pulmonary organ involvement that was suggestive of TB
(e.g., pericardial effusion or abdominal lymphadenopathy
on ultrasound) or if the physician documented a suspi-
cion for extrapulmonary TB in the chart. MDR-TB was
defined as resistance to at least isoniazid and rifampicin,
w h i l eX D R - T Bw a sd e f i n e da sr e s i s t a n c et oa tl e a s ti s o -
niazid, rifampicin, kanamycin and ofloxacin [25]. Sus-
ceptibility testing to other second-line TB drugs was not
routinely done.
The primary outcome was the yield of blood cultures
for drug-resistant TB, defined as the proportion of
blood cultures that were positive for MDR or XDR-TB.
Secondary outcomes included: 1) risk factors of M.
tuberculosis bacteremia, and 2) comparison of blood cul-
ture to sputum culture for additive yield of blood in
detection of M. tuberculosis and drug resistance.
Laboratory methods
All patients had 5 ml of blood collected and inoculated
into mycobacterial blood culture bottles (BACTEC
MycoF-lytic) and placed in a darkened storage container
at room temperature prior to transport to the provincial
referral laboratory. Blood culture bottles were cultured
using the automated BACTEC 9240 system in which
specimens are continuously monitored for growth up to
42 days [26]. All positive cultures were confirmed by
niacin accumulation and nitrate reductase methods.
DST was performed on all specimens positive for M.
tuberculosis using the 1% proportional method [27] on
Middlebrook 7H11 agar to: isoniazid (critical concentra-
tion, 0.2 μg/ml), rifampicin (1 μg/ml), ethambutol (7.5
μg/ml), ofloxacin (2 μg/ml), kanamycin (6 μg/ml) and
streptomycin (2 μg/ml). Non-tuberculous mycobacteria
(NTM) were not further speciated.
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transport to the provincial TB referral laboratory. Upon
receipt, the specimen was digested and decontaminated
with the N-acetyl-L-cysteine-sodium hydroxide method
and smears were prepared for auramine staining. The
remainder of the deposit was transferred for liquid cul-
ture in the automated BACTEC MGIT 960 system. DST
was completed on all positive specimens after secondary
inoculation on to Middlebrook 7H11 agar and using the
1% proportional method for the drugs as described with
blood specimens.
Statistical analysis
Yield of M. tuberculosis detected by blood and sputum
was calculated using simple frequencies and proportions.
Demographic and clinical characteristics were compared
with the chi-square statistic or the Mann-Whitney U
test for non-parametric data. Bivariate and multivariate
logistic regression were employed to determine risk fac-
tors for M. tuberculosis bacteremia. All tests for signifi-
cance were 2-sided with a p-value < 0.05 considered
significant. For variables with >10% missing data, tests
of interaction were performed when appropriate. The
multivariate model included any variable with p-value <
0.1 in bivariate analysis and any pertinent clinical and
demographic characteristics. All analysis was performed
using SPSS Statistics 17.0 software.
Ethical considerations
The study was approved by the biomedical research
ethics committees of the University of KwaZulu-Natal,
Albert Einstein College of Medicine, and Yale
University.
Results
One-hundred thirty patients suspected of drug-resistant
TB had mycobacterial blood cultures performed during
the study period and were included for analysis. All
patients had only one blood culture specimen. There
were 73 males (56%); the median age was 31.5 years
(Interquartile range [IQR] 27-38) and 8 (6%) patients
were less than 12 years of age (Table 1). HIV-infection
was confirmed in 114 (88%) patients. The CD4 cell
count was available in 63 (55%) HIV-infected patients,
with a median cell count of 100 cells/mm
3 (IQR 28-
190). Fifty-three (46%) HIV-infected patients were on
antiretroviral therapy at the time of blood culture collec-
tion. The median duration of antiretroviral therapy for
patients on treatment was 15.4 weeks (IQR 4.7-31.0).
Of the 130 patients, 88 (68%) had no prior history of
TB, although 89 (69%) patients were failing drug-suscep-
tible TB treatment at the time of blood culture collec-
tion. The median duration of TB treatment for these
patients was 8.0 weeks (IQR 4.0-20.0). Forty-five (35%)
patients were suspected to have extrapulmonary TB.
Overall yield of mycobacterial blood cultures
Of 130 blood culture specimens, M. tuberculosis was
isolated in 41 (32%) (Table 2). Of the 41 blood cultures
that yielded M. tuberculosis, 28 (68%) were drug-resis-
tant TB. Specifically, 20 (49%) specimens were XDR-TB
and 8 (20%) were MDR-TB (Table 2). Among the blood
cultures positive for XDR-TB, 18 (90%) of 20 were resis-
tant to all six drugs tested.
Of the remaining positive blood cultures, NTM were
found in 3 (6%) specimens and Cryptococcus species was
found in 3 (6%) specimens. In the six study patients
with Cryptoccocus species or NTM detected in the
blood, five were currently receiving first-line TB therapy
at the time of blood culture collection yet none of the
patients had culture documentation of M. tuberculosis.
Risk factors for M. tuberculosis bacteremia
There were significantly more patients with M. tubercu-
losis bacteremia who were extrapulmonary TB suspects,
OR 2.1 [0.97-4.5; p = 0.06]; adjusted OR 2.3 [1.0-5.4; p
= 0.05]. Among HIV-infected patients, those on antire-
troviral therapy for any duration at the time of blood
culture collection were significantly less likely to have
M. tuberculosis bacteremia, OR 0.29 [95% CI, 0.12-0.71;
p = 0.005]; adjusted OR 0.22 [0.08-0.58; p = 0.002]
(Table 1). Though age was not a significant risk factor,
it was found that M. tuberculosis was cultured from the
blood in patients as young as 8 years (MDR-TB) and as
old as 62 years (XDR-TB).
Comparison of blood to sputum cultures for MDR-TB and
XDR-TB yield
Of the 41 patients with M. tuberculosis bacteremia,
there were 23 patients that also had a sputum sample
collected for comparison (Table 3). With two patients,
the sputum sample was negative but the blood cultures
revealed XDR-TB in one and MDR-TB in the other.
DST was not completed in one patient’s sputum sample
but the blood culture revealed XDR-TB. Among all
patients in whom DST was completed in both the blood
and sputum sample, the DST results were identical.
Considering the 21 patients where sputum cultures were
either negative, DST was incomplete, or sputum was
not collected, there were 9 (43%) blood cultures that
diagnosed drug-susceptible TB and 12 (57%) that diag-
nosed MDR or XDR-TB (Table 3). Despite extrapul-
monary TB suspects being at higher risk of M.
tuberculosis bacteremia, in patients with both a blood
and a sputum culture positive for M. tuberculosis,o n l y
24% were suspected of extrapulmonary TB.
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We found that among a predominantly HIV-infected
population of patients suspected of drug-resistant TB,
MDR-TB and XDR-TB were isolated in nearly 70% of
all positive M. tuberculosis blood cultures. Importantly,
among patients with MDR or XDR-TB bacteremia, in
over half of those in whom a sputum culture was
unavailable, the blood culture was the only means of
drug-resistant TB diagnosis. Bacteremia with XDR-TB
was more common than MDR-TB, but reflective of
community trends from sputum diagnosis in Tugela
Ferry [28].
Current guidelines suggest the use of mycobacterial
blood cultures may be beneficial in suspected
Table 1 Demographic and clinical characteristics compared by patients with and without M. tuberculosis (MTB)
bacteremia
Characteristic Total
n (%)
Blood culture positive
for MTB, n (%)
Blood culture negative
for MTB, n (%)
Bivariate relative risk [95%
confidence interval],
p-value
Total n = 130 n = 41 n = 89
Sex:
Male 73 (56) 22 (54) 51 (57) 1.16 [0.55-2.4] p = 0.70
Female 57 (44) 19 (46) 38 (43) referent
Age range (years):
0-14 8 (6) 1 (2) 7 (8) 0.42 [0.05-3.7] p = 0.43
15-25 15 (11) 7 (17) 8 (9) 2.57 [0.81-8.2] p = 0.11
26-35 67 (52) 17 (41) 50 (56) referent
36-45 28 (22) 11 (27) 17 (19) 1.9 [0.75-4.9] p = 0.18
> 45 12 (9) 5 (12) 7 (8) 2.1 [0.59-7.5] p = 0.25
Prior history of TB treatment
Yes 42 (32) 15 (37) 27 (30) 1.33 [0.61-2.9] p = 0.48
No 88 (68) 26 (63) 62 (70) referent
Currently on first-line TB treatment
Yes 89 (69) 28 (68) 61 (69) 0.99 [0.45-2.2] p = 0.98
No 41 (31) 13 (32) 28 (31) referent
Duration of TB treatment for patients on
treatment (median weeks)
[IQR]
8 [4.0-
20.0]
10 [4.0-24] 8 [5.5-13.5] p = 0.76
Clinical features extrapulmonary TB
Yes 45 (35) 19 (46) 26 (29) 2.10 [0.97-4.5] p = 0.06
No 85 (65) 22 (54) 63 (71) referent
HIV status:
Positive 114 (88) 34 (83) 80 (90) p > 0.99
Negative 1 (1) 0 (0) 1 (1) referent
Unknown 15 (11) 7 (17) 8 (9) p > 0.99
CD4 count
a (median cells/mm
3)
[IQR]
100
b
[28-190]
92 [81-174] 104 [21-222] p = 0.82
CD4 count cells/mm
3
0-100 32 (51) 24 (50) 8 (54) 1.92 [0.35-10.5] p = 0.45
101-200 17 (27) 12 (25) 5 (33) 2.73 [0.44-17.1] p = 0.29
> 200 14 (22) 12 (25) 2 (13) referent
Receiving antiretroviral therapy
c
Yes 53 (47) 9 (26) 44 (55) 0.29 [0.12-0.71] p = 0.005
No 61 (53) 25 (72) 36 (45) referent
Duration of antiretroviral therapy(median
weeks)
[IQR]
15 [4-31] 16 [7-32] 15 [5-30] p = 0.92
IQR = interquartile range.
a Available in 63 (55%) of 114 HIV-infected patients.
b CD4% in 3 pediatric cases (7.0%, 6.0% and 7.9%)
cAvailable in 114 (100%) HIV-infected patients.
Heysell et al. BMC Infectious Diseases 2010, 10:344
http://www.biomedcentral.com/1471-2334/10/344
Page 4 of 7extrapulmonary TB, but do not address the use in all
HIV-infected persons or those suspected of drug-resis-
tant TB [29]. A recent comprehensive screening study
of HIV-infected ambulatory persons from Southeast
Asia found only a 5% incremental yield of blood cul-
tures for TB diagnosis among those with two negative
sputum smears; DST results w e r en o tp r o v i d e d[ 1 9 ] .I n
contrast, the results from our study population are likely
reflective of advanced immunosuppression, prolonged
TB illness prior to blood culture collection, and the high
pretest suspicion of drug-resistant TB. The additive yield
of blood cultures is likely to vary in other regions with
differing disease epidemiology. Nonetheless, these results
suggest that M. tuberculosis bacteremia is likely to be
present in drug-resistant TB suspects at higher rates
than clinically suspected. Thus, we feel that these results
are generalizable to other populations in sub-Saharan
Africa where TB/HIV co-infection rates are high and
the incidence of drug-resistant TB may be increasing.
The bulk of the additive yield for MDR and XDR-TB
in blood compared to sputum cultures was found in
patients that did not have a sputum sample collected.
The most common reason to not have a sputum sample
collected in this hospital is the patient’s inability to
expectorate due to an absence of cough or marked phy-
sical disability; however, due to the retrospective nature
of this study, we cannot confirm the reasoning for an
individual patient. Standard of practice in other settings
is to collect two or more sputum samples for micro-
scopy and/or TB culture as a means of increasing yield.
Further prospective study is warranted to determine
how multiple sputum samples would affect the com-
parative yield to blood culture in similar populations
with advanced HIV. Blood is an easily accessible fluid
and carries the additional advantage of not requiring
cold storage for transport. Additionally, the cost of ana-
lyzing a mycobacterial blood culture with the National
Health Services Laboratory in South Africa is no more
expensive than MGIT analysis of a sputum specimen.
In this study, the majority of patients with M. tubercu-
losis bacteremia were not suspected to have extrapul-
monary TB. Mycobacterial culture of lymph node
aspirates and pleural fluid were available to clinicians
during this study period [11], yet in only three patients
was an aspirate performed and all were concordant with
blood culture results. Indeed, the minority of patients
with positive blood cultures and sputum cultures for M.
tuberculosis were suspected of extrapulmonary TB.
Thus, our findings suggest that many patients with pul-
monary TB in this setting may also harbor unrecognized
M. tuberculosis bacteremia. Detection of otherwise
occult M. tuberculosis bacteremia regardless of DST, in
a patient without suspected extrapulmonary TB may
Table 2 Overall yield of mycobacterial blood cultures for
diagnosis of drug-susceptible, multidrug-resistant (MDR)
and extensively drug-resistant (XDR) tuberculosis (TB)
n (%)
Blood culture result (n = 130):
M. tuberculosis 41
(32)
Non-tuberculous mycobacteria 3 (2)
Cryptococcus sp. 3 (2)
Other
a 5 (4)
Negative 78
(60)
Drug-susceptibility results among M. tuberculosis isolates (n =
41):
XDR-TB 20
(49)
MDR-TB
b 8 (20)
Drug-susceptible 10
(24)
Incomplete
c 3 (7)
a Other bacterial species, possible contaminants.
b All MDR-TB specimens were also resistant to streptomycin.
c M. tuberculosis identified, susceptibility results not available.
Table 3 Sputum culture results among patients with a positive blood culture for M. tuberculosis (n = 41)
Blood culture drug-susceptibility test result
DS TB MDR-TB XDR-TB DST incomplete
Sputum culture result DS TB 4
MDR-TB 4
XDR-TB 12
DST incomplete
a 1
No growth 1 1
Not collected 6 3 6 3
Additive yield of blood by DST category 6 (60%) 4 (50%) 8 (40%) 3 (100%)
DS TB = drug-susceptible TB.
MDR-TB: Multidrug-resistant tuberculosis.
XDR-TB: Extensively drug-resistant tuberculosis.
DST: drug-susceptibility test.
a M. tuberculosis identified, but DST not available.
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focus which could alter treatment and carry important
implications for monitoring and clinical outcome.
Patients on antiretroviral medication at the time of
blood culture collection were significantly less likely to
have M. tuberculosis bacteremia. Earlier studies of M.
tuberculosis bacteremia in similar populations in Africa
were carried out prior to widespread availability of anti-
retrovirals and therefore this association could not have
been documented until now [20,21]. Our findings lend
further support to the growing body of evidence for
early initiation of antiretrovirals in the treatment of TB
and HIV co-infected patients [30]. Notably, the median
duration of antiretroviral use in our study population
was 15 weeks, a reasonable timeframe to present with
immune reconstitution inflammatory syndrome (IRIS).
We suspect that some patients on antiretroviral therapy
who were culture-negative for TB may have actually
presented with IRIS, a condition which may share signs
and symptoms with TB and drug-resistant TB; however
complete follow-up data were not available for confir-
mation. Interestingly, there was no difference in CD4
count among patients with and without M. tuberculosis
bacteremia. One explanation is, in accord with national
guidelines, the CD4 count is only checked twice
annually; thus the CD4 count recorded may be falsely
low for those patients that initiated antiretroviral ther-
apy within the prior six months. Alternatively, in some
patients early restoration of lymphocyte function may
precede restoration of total lymphocyte count.
One of the primary limitations of the study, given its
retrospective design, was that the decision of blood cul-
ture collection was dependent upon the attending clini-
cian and therefore additional patients suspected of drug-
resistant TB may not have had blood cultures sent and
were not included in the study. Additional factors that
influenced the decision to pursue the investigation for
M. tuberculosis bacteremia may not have been captured.
It is also a possibility that blood cultures may have been
preferentially pursued in patients in whom a diagnosis
was not as readily made by sputum analysis. Therefore,
only prospective study of simultaneous blood and rigor-
ous collection of multiple sputum samples in all drug-
resistant TB suspects would allow determination of a
true incremental yield in this setting.
Conclusions
In summary, mycobacterial blood cultures diagnosed
MDR and XDR-TB in a substantial number of patients
predominately HIV-infected and suspected of drug-resis-
tant TB from rural South Africa. Bacteremia with drug-
susceptible and drug-resistant TB was not restricted to
patients suspected of extrapulmonary TB, as many
patients with sputum culture confirmed pulmonary TB
also had M. tuberculosis bacteremia. The adjunctive use
of mycobacterial blood cultures should be considered in
all patients suspected of drug-resistant TB, particularly
in those unable to expectorate. In many regions of
Africa and the developing world, culture and DST are
not routinely performed for the diagnosis of TB despite
the inferior sensitivity of routine sputum microscopy
and the inability of microscopy to detect drug-resistant
TB. Expanded access to culture and DST of sputum in
South Africa has been projected to save 47,955 lives and
avert 7,721 new MDR-TB cases over the next 10 years
[31]. Our finding that a significant proportion of drug-
resistant TB suspects had MDR-TB or XDR-TB bactere-
mia underscores the need for more widespread use of
culture and DST for both sputum and blood specimens.
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